References
- Lee DYW, Li QY, Liu J, Efferth T. Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis. Phytomedicine. 2021; 80:153337. doi: 10.1016/j.phymed.2020.153337
- World Health Organization. Expert panel endorses protocol for COVID-19 herbal medicine clinical trials [internet]. Brazzaville, Republic of Congo: World Health Organization - Regional Office for Africa; 2020 [cited 2020 November 28]. Available from: https://www.afro.who.int/news/expert-panel-endorses-protocol-covid-19-herbal-medicine-clinical-trials
- Russo M, Moccia S, Spagnuolo C, Tedesco I, Russo GL. Roles of flavonoids against coronavirus infection. Chem Biol Interact. 2020; 328:109211. doi: 10.1016/j.cbi.2020.109211
- Peterson L. COVID-19 and flavonoids: in silico molecular dynamics docking to the active catalytic site of SARS-CoV and SARS-CoV-2 main protease. SSRN Electronic J. 2020. doi: 10.2139/ssrn.3599426
- Jahan I, Onay A. Potentials of plant-based substance to inhabit and probable cure for the COVID-19. Turkish J Biol 2020; 44(Special Issue 1):228–41.
- Orhan IE, Senol Deniz FS. Natural products as potential leads against coronaviruses: could they be encouraging structural models against SARS-CoV-2? Nat Products Bioprospect. 2020; 10:171–86.
- Benarba B, Pandiella A. Medicinal plants as sources of active molecules against COVID-19. Front Pharmacol. 2020; 11:1–16.
- Yu S, Yan H, Zhang L, Shan M, Chen P, Ding A, Li SF. A review on the phytochemistry, pharmacology, and pharmacokinetics of amentoflavone, a naturally-occurring biflavonoid. Molecules. 2017; 22:299. doi: 10.3390/molecules22020299
- Chen T-R, Wei L-H, Guan X-Q, Huang C, Liu Z-Y, Wang F-J, et al. Biflavones from Ginkgo biloba as inhibitors of human thrombin. Bioorg Chem. 2019; 92:103199. doi: 10.1016/j.bioorg.2019.103199
- Ma S-C, But PP-H, Ooi VE-C, He Y-H, Lee SH-S, Lee S-F, Lin R-C. Antiviral amentoflavone from Selaginella sinensis. Biol Pharm Bull. 2001; 24:311–2.
- Li F, Song X, Su G, Wang Y, Wang Z, Jia J, et al. Amentoflavone inhibits HSV-1 and ACV-resistant strain infection by suppressing viral early infection. Viruses 2019; 11:466. doi: 10.3390/v11050466.
- Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH. Inhibitory effects of amentoflavone and orobol on daclatasvir-induced resistance-associated variants of hepatitis C virus. Am J Chin Med. 2018; 46:835–52.
- Wilsky S, Sobotta K, Wiesener N, Pilas J, Althof N, Munder T, et al. Inhibition of fatty acid synthase by amentoflavone reduces coxsackievirus B3 replication. Arch Virol. 2012; 157:259–69.
- Coulerie P, Nour M, Maciuk A, Eydoux C, Guillemot J-C, Lebouvier N, et al. Structure-activity relationship study of biflavonoids on the Dengue virus polymerase DENV-NS5 RdRp. Planta Med. 2013; 79:1313–8.
- Bhargava S, Patel T, Gaikwad R, Patil UK, Gayen S. Identification of structural requirements and prediction of inhibitory activity of natural flavonoids against Zika virus through molecular docking and Monte Carlo based QSAR Simulation. Nat Prod Res. 2019;33:851–7.
- Ullrich S, Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorganic Med Chem Lett. 2020; 30:127377. doi: 10.1016/j.bmcl.2020.127377
- Ryu YB, Jeong HJ, Kim JH, Kim YM, Park JY, Kim D, et al. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition. Bioorganic Med Chem 2010; 18:7940–7.
- Jo S, Kim S, Shin DH, Kim M-S. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem. 2020;35:145–51.
- Mishra A, Pathak Y, Kumar A, Mishra SK, Tripathi V. Natural compounds as potential inhibitors of SARS-CoV-2 main protease: an in-silico study. Asian Pac J Trop Biomed. 2021; 11:155–63.
- Miroshnychenko KV. Shestopalova A. Combined use of the hepatitis C drugs and amentoflavone could interfere with binding of the spike glycoprotein of SARS-CoV-2 to ACE2: the results of a molecular simulation study. J Biomol Struct Dyn. 2021 Apr 26;1–15. [Online ahead of print]. doi: 10.1080/07391102.2021.1914168
- National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. Bethesda, MD: National Institutes of Health; 2021 [cited 2021 July 13]. Available at: https://www.covid19treatmentguidelines.nih.gov/
- Iannaccone G, Scacciavillani R, Del Buono MG, Camilli M, Ronco C, Lavie CJ, et al. Weathering the cytokine storm in COVID-19: therapeutic implications. Cardiorenal Med. 2020; 10:277–87.
- Torres Acosta MA, Singer BD. Pathogenesis of COVID-19-induced ARDS: implications for an ageing population. Eur Respir J. 2020; 56:2002049. doi: 10.1183/13993003.02049-2020
- Diniz LRL, Bezerra Filho CdSM, Fielding BC, de Sousa DP. Natural antioxidants: a review of studies on human and animal coronavirus. Oxid Med Cell Longev 2020; 2020:3173281. doi: 10.1155/2020/3173281
- Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015; 43(D1):D447–52.
- Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: Augmenting protein–chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2016; 44(D1):D380–4.
- Oh J, Rho HS, Yang Y, Yoon JY, Lee J, Hong YD, et al. Extracellular signal-regulated kinase is a direct target of the anti-inflammatory compound amentoflavone derived from Torreya nucifera. Mediators Inflamm. 2013; 2013:761506. doi: 10.1155/2013/761506.
- Zong Y, Zhang H. Amentoflavone prevents sepsis-associated acute lung injury through Nrf2-GCLc-mediated upregulation of glutathione. Acta Biochim Pol. 2017; 64:93–8.
- Cai J, Zhao C, Du Y, Huang Y, Zhao Q. Amentoflavone ameliorates cold stress-induced inflammation in lung by suppression of C3/BCR/NF-κB pathways. BMC Immunol. 2019; 20:49. doi: 10.1186/s12865-019-0331-y
- Gan L, Ma J, You G, Mai J, Wang Z, Yang R, et al. Glucuronidation and its effect on the bioactivity of amentoflavone, a biflavonoid from Ginkgo biloba leaves. J Pharm Pharmacol. 2020; 72:1840–53.
- Kimura Y, Ito H, Ohnishi R, Hatano T. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol. 2010; 48:429–35.
- Park S-Y, Nguyen P-H, Kim G, Jang S-N, Lee G-H, Phuc NM, et al. Strong and selective inhibitory effects of the biflavonoid selamariscina A against CYP2C8 and CYP2C9 enzyme activities in human liver microsomes. Pharmaceutics. 2020; 12:343. doi: 10.3390/pharmaceutics12040343
- Pan X, Tan N, Zeng G, Zhang Y, Jia R. Amentoflavone and its derivatives as novel natural inhibitors of human Cathepsin B. Bioorganic Med Chem. 2005; 13:5819–25.
- Lv X, Zhang J-B, Wang X-X, Hu W-Z, Shi Y-S, Liu S-W, et al. Amentoflavone is a potent broad-spectrum inhibitor of human UDP-glucuronosyltransferases. Chem Biol Interact. 2018;284:48–55.
- Ananchaisarp T, Rungruang S, Theerakulpisut S, Kamsakul P, Nilbupha N, Chansawangphop N, et al. Usage of herbal medicines among the elderly in a primary care unit in Hat Yai, Songkhla province, Thailand. Asian Biomed (Res Rev News) 2021; 15:35–42.
- Stolbach A, Paziana K, Heverling H, Pham P. A review of the toxicity of HIV medications II: interactions with drugs and complementary and alternative medicine products. J Med Toxicol. 2015; 11:326–41.
- Borrelli F, Izzo AA. Herb–drug interactions with St John's Wort (Hypericum perforatum): an update on clinical observations. AAPS J. 2009; 11:710–27.
- Lobstein-Guth A, Briançon-Scheid F, Victoire C, Haag-Berrurier M, Anton R. Isolation of amentoflavone from Ginkgo biloba. Planta Med. 1988; 54:555–6.
- Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry. 1997; 30:129–34.
- Chrubasik-Hausmann S, Vlachojannis J, McLachlan AJ. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content. J Pharm Pharmacol. 2019; 71:129–38.
- Deng Y, Bi H-C, Zhao L-Z, He F, Liu Y-Q, Yu J-J, et al. Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats. Xenobiotica 2008; 38:465–81.
- Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020; 323:1824–36.
- Huynh T, Wang H, Cornell W, Luan B. In silico exploration of repurposing and optimizing traditional Chinese medicine rutin for possibly inhibiting SARS-CoV-2's main protease. ChemRxiv. Preprint. 2020. doi: 10.26434/chemrxiv.12281078.v1